Pardes Biosciences, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering, developing and commercializing therapeutics to improve the lives of patients suffering from life-threatening diseases. Its lead candidate, PBI-0451, is in clinical development and is developed to treat and prevent coronaviral (CoV) infections. It has built a discovery platform designed to target reactive nucleophiles. The Company by leveraging its knowledge of structure-based drug design, reversible covalent chemistry and viral biology, has discovered and is developing product candidates with low nanomolar potency against SARS-CoV-2 and activity against all known pathogenic human coronaviruses. The Company's lead product candidate, PBI-0451, inhibits the main coronaviral cysteine protease, or Mpro, a viral protein essential for replication of all known coronaviruses, including SARS-CoV-2. The PBI-0451 product candidate is in Phase I clinical development.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Annual Dividend Rate
Price/Cash Flow (TTM)